Dear Colleagues,

Metabolic disorders—including obesity, diabetes, hypertension, dyslipidemia, and metabolic syndrome (MetS)—play a critical role in the initiation, progression, and adverse outcomes of cardiovascular disease. Previous studies have shown that individuals with MetS have a threefold higher risk of developing cardiovascular disease and a twofold higher risk of cardiovascular events than do those without MetS. Moreover, a large-cohort study based on the UK Biobank data, involving 325,129 participants, demonstrated that metabolic dysfunction-associated fatty-liver disease is significantly associated with an increased risk of myocardial infarction.

Chronic low-grade inflammation is recognized as a key contributor throughout the entire course of coronary artery disease (CAD), and is considered a major driver of vulnerable plaque rupture. Patients with metabolic disorders such as dyslipidemia, hypertension, and diabetes often exhibit persistent systemic inflammation, which may further accelerate the development and progression of CAD. Therefore, exploring the bridging role of chronic low-grade inflammation between metabolic disorders and CAD is essential for clarifying the underlying pathophysiological mechanisms.

We welcome the review article, systematic review, original research, short communication, opinion, editorial, commentary and letter to the editor/reply related to this Special Issue theme. Novel insights into these mechanisms may help improve the risk stratification and clinical outcomes of patients with CAD.

Xin Zhao and Yan Chen
Guest Editors